Celularity Inc. (NASDAQ:CELUW – Get Rating) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 18,300 shares, a growth of 190.5% from the January 31st total of 6,300 shares. Based on an average daily volume of 14,200 shares, the short-interest ratio is currently 1.3 days.
Celularity Stock Performance
Shares of Celularity stock opened at $0.08 on Wednesday. Celularity has a one year low of $0.06 and a one year high of $1.99. The firm has a 50-day moving average price of $0.09.
Get Celularity alerts:Celularity Company Profile
(Get Rating)
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
Featured Stories
- Get a free copy of the StockNews.com research report on Celularity (CELUW)
- Will Q4 Results Send Zoom Video Stock Higher?
- Is Amazon a Blue Chip Stock?
- Occidental Petroleum Pulls Back To The Sweet Spot
- Should You Take a Cruise in Royal Caribbean Stock?
- Is Target Stock Aiming For A Breakout In 2023?
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.